Emergent biosolutions gains exclusive commercial rights to kloxxado® (naloxone hci) nasal spray from hikma pharmaceuticals

Gaithersburg, md., jan. 14, 2025 (globe newswire) -- emergent biosolutions inc. (nyse: ebs) announced today that it has entered into an agreement to obtain exclusive commercial rights in the u.s. and canada to hikma pharmaceuticals' kloxxado® (naloxone hcl) nasal spray, an 8 mg naloxone agent that is approved for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.1 this six-year agreement complements and strengthens emergent's mission to protect, enhance, and save lives by helping to reduce opioid overdose deaths —providing compelling product options, combined with a commitment to increasing naloxone access, awareness, and education.
HCI Ratings Summary
HCI Quant Ranking